The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges.

Plerixafor is effective across multiple diagnoses using an oncologist-driven HSC collection endpoint. Its association with mobilization failure is likely attributable to its use in patients predicted to be poor mobilizers.